Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Provided By PR Newswire
Last update: May 27, 2025
Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026
Read more at prnewswire.com162.8
-2.73 (-1.65%)
1.44
-0.04 (-2.7%)
Find more stocks in the Stock Screener
